DRG Epidemiology's coverage of autism spectrum disorder comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of autism spectrum disorder for each country, as well as annualized case counts projected to the national population.

The patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. DRG Epidemiology's autism spectrum disorder forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of autism spectrum disorder over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for autism spectrum disorder subtypes.

Note: Coverage may vary by country and region.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Overviews
        • Prevalence of Autism Spectrum Disorder (DSM-IV criteria) per 1,000 Among People Aged 15 or Older in 2017 and 2037
        • Prevalence of Autism Spectrum Disorder (DSM-5 criteria) per 1,000 Among People Aged 15 or Older in 2017 and 2037
        • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Autism Spectrum Disorder Over the Next 20 Years
        • Analysis of Diagnosed Prevalent Cases of Autism Spectrum Disorder (DSM-IV criteria) Across the Countries Under Study in 2017, by Subtype
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases of Autism Spectrum Disorder (DSM-IV)
      • Total Prevalent Cases of Autism Spectrum Disorder (DSM-5)
      • Autism Spectrum Disorder Subtype
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Alison Isherwood, MSc, MRes, PhD

Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Autism Spectrum Disorder | Landscape & Forecast | Disease Landscape & Forecast

Autism spectrum disorder (ASD) is a heterogeneous, neurodevelopmental disorder with core symptoms including deficits in social interaction, difficult...

View Details